Search PubMed⌕ Search

Biomedical subjects

J Dequeker

Publications and source records attributed to J Dequeker.

At least 253 records · Page 14Linked to original sources
PubMed1984

Effects of pregnancy on bone matrix proteins in Wistar rats.

Using an EDTA extraction procedure, bones from pregnant Wistar rats were analyzed for their content of collagen and non-collagenous components (sialoprotein, proteoglycan and carbohydrate). The bone matrix size was found to be smaller in pregnant rats than in normal rats (19.5% vs 17.5% of the dry weight bone). The EDTA extractability of the bone protein from pregnant rats was higher than that from controls (2.6% vs 1.9% dry weight bone). EDTA extracts from pregnant rats contained higher amounts of soluble collagen (1.6% vs 0.5% of dry weight tissue) and lower amounts of non-collagenous components (1.65% vs 2.23% for hexoses, 2.38% vs 3.95% for sialic acid and 1.24% vs 1.73% for uronic acid). In bone matrix, collagen content was lower in the pregnant rats (9.45% vs 10.6%). Similarly, the amounts of non-collagenous components were slightly decreased in the bone matrix from the pregnant rats. The respective values were: 0.91% vs 0.93% for hexoses, 0.45% vs 0.52% for sialic acid and 0.39% vs 0.50% for uronic acid. These results suggest that in pregnancy collagen and non-collagenous protein content in bone is decreased while the total mineral content is increased.

Animals↗
PubMed1984

A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis.

One hundred sixty-two consecutive patients with rheumatoid arthritis (RA) were studied for possible association between HLA antigens, particularly DR antigens, and disease characteristics and adverse reactions to gold or D-penicillamine treatment. The frequency of HLA-DR4 was significantly increased: 62% in RA compared to 23% in controls. An association of HLA-DR4 with a positive family history for RA was also found. HLA-DR4 was not associated with subcutaneous nodules or keratoconjunctivitis, presence of rheumatoid factor, or ANA positivity. No increased prevalence of HLA-DR3 was found in patients who developed drug related toxicity (e.g., proteinuria for gold or D-penicillamine). Of the 27 patients in whom proteinuria developed, only 5 were DR3 positive. A significant association with D-penicillamine induced proteinuria and HLA-B8 gene was found. Our results obtained in a systematic survey do not confirm previous reports of a significant association between HLA-DR3 and drug toxicity, but confirm the association between HLA-DR4 and the development of RA and HLA-B8 and D-penicillamine induced proteinuria.

Adolescent↗
PubMed1983

Osteoporosis and osteoarthritis (osteoarthrosis). Anthropometric distinctions.

Anthropometric and skin-fold characteristics were studied in 27 women with symptomatic osteoporosis of the postmenopausal type and in 25 women with generalized osteoarthritis. In several aspects, important and significant differences were found between both groups. It was shown that the osteoporotic women were shorter, more slender, and had less fat, muscle girth, and strength, while the women with osteoarthritis, although of comparable age and skeletal size, were more obese and had more fat, muscle mass, and strength. These findings support the idea that osteoarthritis and osteoporosis are two different disease entities and not simple phenomena of aging and wear and tear.

Aged↗
PubMed1983

Effect of lymphoplasmapheresis on clinical indices and T cell subsets in rheumatoid arthritis. A double-blind controlled study.

The effects of lymphoplasmapheresis on immunologic indices, including T cell subsets, and on clinical parameters of rheumatoid arthritis were evaluated in a controlled double-blind trial. Twenty patients were randomized to receive either 6 lymphoplasmapheresis sessions or a seemingly identical control procedure over a 3-week period. Lymphoplasmapheresis produced significant reduction in serum levels of total lymphocytes, erythrocyte sedimentation rate, C-reactive protein, and IgG. These serologic measures returned to baseline 5 weeks after lymphoplasmapheresis. No change in the imbalance of T cell subsets (increased helper/suppressor ratio) was observed. No changes in the serologic measures, except IgA, were observed in the control group. An improvement in some of the clinical parameters was observed in both the lymphoplasmapheresis and control groups. A rebound above baseline values for several parameters was observed in both the lymphoplasmapheresis and the sham apheresis groups.

Adult↗
PubMed1983

A comparative trial of timegadine and D-penicillamine in rheumatoid arthritis.

Forty-four patients with definite or classical rheumatoid arthritis were entered in a 48-week open study, comparing the long-term effects of Timegadine and D-penicillamine. Twenty-three and 21 patients were respectively allocated to the Timegadine and D-penicillamine groups. Two patients of the former group were lost for follow-up, soon after the first baseline. Thus data were available only for 42 patients, 21 in each group of whom eleven completed the 48-week period in each group. Seven patients in the Timegadine group stopped because of ineffectiveness, 2 because of skin eruption and 1 because of acute interstitial pneumonitis. In the D-penicillamine group, 9 patients dropped out: 3 because of proteinuria, 2 because of stomatitis, 1 because of dizziness and 1 because of headache. Pain (visual analogue scale), number of swollen and painful joints improved significantly in both groups (p less than 0.05). The acute phase reactants alpha1-acid-glycoprotein and ESR and the thrombocyte count significantly decreased in the penicillamine group (p less than 0.05). The other clinical, hematological and immunological tests did not change; neither did the liver and kidney function tests. The clinical results suggest that Timegadine is as effective as D-penicillamine in the treatment of rheumatoid arthritis. D-penicillamine takes advantage over Timegadine by decreasing significantly the acute phase reactants. However, Timegadine has a low profile of side-effects.

Adult↗
PubMed1983

Piroxicam versus naproxen in rheumatoid arthritis.

Forty-five patients with definite or classical rheumatoid arthritis were randomly allocated into two groups and treated with piroxicam 20 mg once daily or naproxen 250 mg twice daily in a 3-month, double-blind study. The results were available in 38 patients (21 in the piroxicam group and 17 in the naproxen group). Both drugs showed significant effects on the majority of clinical parameters compared to baseline. However, piroxicam was significantly superior to naproxen in reducing the grade of swollen joints. Moreover, piroxicam had better efficacy as shown by the number of patients who preferred it to previous therapy; 13 (62% of the patients entered) compared to 8 patients (47%) who preferred naproxen. Tolerance of the two drugs was similar. Two patients in each group dropped out due to side-effects.

Adult↗
PubMed1983

Fentiazac in rheumatoid arthritis: comparison with sulindac and long-term tolerance.

Forty patients with definite or classical rheumatoid arthritis were entered for 3 months in a double-blind trial, 20 patients on 400 mg fentiazac or 200 mg sulindac daily. Statistically significant improvements on fentiazac were reported during the course of the study for 3 of 7 parameters: pain score, total joint score and number of swollen joints, while for sulindac a significant improvement was reported for 6 parameters: pain score, grip strength, joint size, total joint score, number of swollen joints and erythrocyte sedimentation rate. Side-effects were reported during the 3-month comparative period for 3 patients receiving fentiazac, consisting of rash, headache, epigastric pain, and for 1 patient receiving sulindac who suffered from gastro-intestinal intolerance. Because of ineffectiveness and/or side-effects, the treatment had to be discontinued for 5 patients in the fentiazac group and for 3 in the sulindac treatment group. The results support earlier evidence that fentiazac and sulindac have analgesic and anti-inflammatory properties controlling disease activity in rheumatoid arthritis, sulindac being the more effective. During a long-term tolerance study, 3 of 33 patients continued on fentiazac developed a reversible hepatotoxicity possibly due to the drug.

Acetates↗
PubMed1983

Respiratory muscle dysfunction in systemic lupus erythematosus.

An assessment of pulmonary mechanics revealed weakness of inspiratory and expiratory muscles as cause of the restrictive ventilatory defect (vital capacity: 47 +/- 10 percent predicted) in seven (ages 33 to 62 years) out of 26 consecutive patients with systemic lupus erythematosus (SLE). Maximal inspiratory transdiaphragmatic pressures were reduced mainly due to the markedly increased (more positive) esophageal pressures. During maximal expiratory efforts, esophageal and gastric pressures were grossly decreased. These abnormalities probably may be considered part of a more generalized, yet subclinical muscle disorder due to the SLE with, however, predominant involvement of the respiratory muscles. The abnormalities were not related to the use of corticosteroids or generalized inanition. The static expiratory lung compliance was reduced in all patients (55 +/- 18 percent predicted), but normalized immediately following passive inflation of the lungs to transpulmonary pressures of more than 30 cm H2O in two of the three subjects tested. The volume restriction was not progressive over a period of 38.5 patient-years.

Adult↗
PubMed1983

Age and sex variations of bone matrix proteins in Wistar rats.

Collagen and noncollagenous proteins (NCP) have been studied in Wistar rats according to the age and sex. The total amounts of bone matrix proteins, EDTA extracts and the soluble collagenase resistant fraction (SCRF) decreases with aging while the insoluble collagenase resistant fraction (ICRF) increases. No consistent sex-differences have been observed. In the bone matrix, the sialic acid and hexose contents increase with age, the uronic acid value decreases while hydroxyproline does not change. In the EDTA extracts, the collagen extractability decreases markedly with age, the sialic acid content increases while the hexose and uronic acid contents do not vary. Plasma proteins (albumin, orosomucoid and IgG) also do not change with aging. In the collagenase digests, no age and sex differences were found in the collagen and noncollagenous proteins of the SCRF while in the ICRF a decrease was observed for hexoses, uronic acid and sialic acid and an increase for hydroxyproline from the third month onwards.

Age Factors↗
PubMed1982

Rheumatoid arthritis associated with bronchiolitis obliterans and immunoblastic sarcoma.

A case is reported of a 72 year old man suffering from classical seropositive RA for 10 years. Two months before admission he experienced general illness, fever and itching. Lymph nodes enlargement and hepatosplenomegaly were found. Histologic features of lymph node biopsy were compatible with angioimmunoblastic lymphadenopathy and Lennert lymphoma. Rapidly progressive pulmonary deterioration followed with hilar invasion and honeycombing. Sternal punction, bone biopsy, bronchus biopsy and blind lung biopsy however, did not reveal lymphomatous invasion. On the contrary, lung biopsy, showed bronchiolitis obliterans, an often fatal, small airway disease whose connection with RA is discussed. Plasmapheresis induced a correction of leucopenia and thrombocytopenia. A fatal evolution evolved within six months. Autopsy revealed diffuse invasion by immunoblastic sarcoma. The clinicopathological entities angioimmunoblastic lymphadenopathy and Lennert lymphoma are referred to. The relationship with autoimmune disorders is stressed.

Aged↗
PubMed1982

Plasma proteins in human cortical bone: enrichment of alpha 2 HS-glycoprotein, alpha 1 acid-glycoprotein, and IgE.

Human cortical bones were extracted with EDTA, and the residue after EDTA extraction was digested with bacterial collagenase. Ten plasma proteins were identified and quantitated in the EDTA extracts. Three of them--IgE, IgD, and alpha 1acid-glycoprotein--had not previously been described in bone or dentine. Five plasma proteins identified in collagenase digests are albumin, IgG, IgA, IgE, and alpha 1acid-glycoprotein. IgE, alpha 1acid-glycoprotein, and alpha 2HS-glycoprotein were found to be concentrated in the bone more than other plasma proteins by factors between 11 and 525. The identification of plasma proteins was facilitated by the addition of polyethylene glycol in agarose gel. The presence of plasma proteins both in EDTA extracts and in collagenase digests suggests their structural role in bone.

Blood Proteins↗
PubMed1982

Long-term progestogen treatment and bone remodelling in peri-menopausal women: a longitudinal study.

In view of the potential adverse consequences of oestrogen treatment, the effects of a progestogen on bone mass and bone remodelling have been evaluated in a longitudinal study. Bone mass and bone remodelling were measured radiogrammetrically in 39 peri-menopausal women who participated in an earlier cross-sectional study and continued to receive progestogen treatment, viz. lynestrenol, 5 mg daily, for 4.5 yr after the first assessment. Follow-up data obtained in untreated peri-menopausal and post-menopausal women and in oestrogen-treated post-menopausal women were used for comparison purposes. Pairs of hand films were measured blind by the same observer. For each pair of films, the average over six metacarpals of periosteal and endosteal width, cortical thickness and cortical area was calculated. In the progestogen-treated group a slight increase in periosteal diameter occurred, comparable to the untreated and oestrogen-treated groups. The increase in endosteal diameter in the progestogen-treated group is half that in the untreated groups, with a resultant smaller loss in cortical thickness in the lynestrenol group as compared with the untreated controls. Although lynestrenol's effectiveness in inhibiting bone resorption seems to be similar to that of oestrogen, the effect is less than that observed in post-menopausal women treated with conjugated equine oestrogens (1.25 mg) or ethinyl oestradiol (0.025 mg).

Adult↗